Intravenous versus subcutaneous route pharmacokinetics of paracetamol (acetaminophen) in palliative care patients: study protocol for a randomized trial (ParaSCIVPallia)

Archive ouverte

Vernant, Marine | Lepoupet, Marie | Creveuil, Christian | Alix, Antoine | Gourio, Charlotte | Peyro-Saint-Paul, Laure | Lelong-Boulouard, Veronique | Guillaume, Cyril

Edité par CCSD -

International audience. Background Among palliative care (PC) patients who are administered paracetamol, the subcutaneous (SC) route is often an alternative to the intravenous (IV) route. Yet pharmacological and clinical data on whether these are equivalent pharmacokinetically are lacking. Many French palliative teams are now empirically using paracetamol by the SC route, but there are no data to support this practice. This trial aims to compare the pharmacokinetic (PK) parameters of paracetomol between the IV and SC routes in PC patients. Methods/design This is a randomized, open, crossover study in two PC centers. The primary endpoints are AUC0-t, AUC0-infinity, Cmax, Vd, and t1/2. All adverse events will be reported for a safety analysis. Twenty adult PC patients with an IV device having spontaneous pain not related to care, with a numeric pain rate scale > 3/10, or having a systematic prescription of paracetamol as the usual treatment will be included. All patients also have to meet all eligibility criteria. Conclusion This is the first study comparing PK parameters for IV paracetamol versus SC paracetamol in PC patients.

Consulter en ligne

Suggestions

Du même auteur

Medication errors reporting in drug clinical trials: Role of the clinical research pharmacist?. Déclaration des erreurs médicamenteuses dans les recherches portant sur le médicament : place du pharmacien des essais cliniques ?

Archive ouverte | Delavoipière, Elodie | CCSD

National audience. The investigational drugs circuit has specific risks, and medication errors may occur in clinical trials, possibly associated with adverse reactions. These risks must therefore be managed. In fact...

Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study

Archive ouverte | Hocqueloux, Laurent | CCSD

International audience. Background Crushing or dissolving bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) tablets is not recommended because there are no data supporting this practice.MethodsA crossove...

Compensating patients in trials: Perspectives from an ethical committee versus sponsor

Archive ouverte | Peyro-Saint-Paul, Laure | CCSD

International audience. Background: According to European clinical research legislation, no undue influence,including financial incentives, should be used to encourage participationin clinical trials. Financial comp...

Chargement des enrichissements...